Market Closed -
Nasdaq
04:00:00 2024-06-07 pm EDT
|
5-day change
|
1st Jan Change
|
20.94
USD
|
+3.66%
|
|
-7.22%
|
+51.30%
|
Fiscal Period: December |
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
570.4
|
984.9
|
-
|
-
|
Enterprise Value (EV)
1 |
570.4
|
822.6
|
939
|
737.3
|
P/E ratio
|
-6.89
x
|
-9.09
x
|
-7.43
x
|
-6.38
x
|
Yield
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
39,398
x
|
39,398
x
|
EV / Revenue
|
-
|
-
|
37,558
x
|
29,491
x
|
EV / EBITDA
|
-6.83
x
|
-6.86
x
|
-5.81
x
|
-3.51
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
41,212
|
47,037
|
-
|
-
|
Reference price
2 |
13.84
|
20.94
|
20.94
|
20.94
|
Announcement Date
|
3/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
0.025
|
0.025
|
EBITDA
1 |
-
|
-
|
-83.53
|
-120
|
-161.5
|
-209.9
|
EBIT
1 |
-
|
-38.79
|
-83.53
|
-115.7
|
-142.1
|
-177.3
|
Operating Margin
|
-
|
-
|
-
|
-
|
-568,225.32%
|
-709,084%
|
Earnings before Tax (EBT)
1 |
-
|
-37.66
|
-71.58
|
-103.2
|
-130.5
|
-168.5
|
Net income
1 |
-24.74
|
-37.66
|
-71.58
|
-103.2
|
-130.5
|
-168.5
|
Net margin
|
-
|
-
|
-
|
-
|
-521,854.68%
|
-673,905.32%
|
EPS
2 |
-3.170
|
-3.560
|
-2.010
|
-2.302
|
-2.820
|
-3.280
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/10/22
|
3/21/23
|
3/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-16.42
|
-20.13
|
-24.25
|
-22.73
|
-25.99
|
-28.26
|
-30.5
|
-30.96
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-14.72
|
-16.72
|
-20.77
|
-19.37
|
-22.74
|
-26.09
|
-27.8
|
-29.15
|
Net income
1 |
-14.72
|
-16.72
|
-20.77
|
-19.37
|
-22.74
|
-26.09
|
-27.8
|
-29.15
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.8000
|
-0.4100
|
-0.5100
|
-0.4700
|
-0.5400
|
-0.5675
|
-0.6200
|
-0.6300
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
5/11/23
|
8/10/23
|
11/9/23
|
3/14/24
|
5/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
162
|
46
|
248
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
-
|
0.72
|
0.9
|
1.13
|
Capex / Sales
|
-
|
-
|
-
|
-
|
3,580%
|
4,504%
|
Announcement Date
|
11/10/22
|
3/21/23
|
3/14/24
|
-
|
-
|
-
|
Last Close Price
20.94
USD Average target price
34.67
USD Spread / Average Target +65.55% Consensus |
1st Jan change
|
Capi.
|
---|
| +51.30% | 985M | | +18.72% | 125B | | +14.19% | 108B | | -4.93% | 24.21B | | +3.23% | 22.78B | | -10.44% | 17.96B | | -41.74% | 16.43B | | -13.31% | 16.37B | | +2.44% | 13.58B | | +27.89% | 11.66B |
Bio Therapeutic Drugs
|